Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years
BackgroundIn Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients.Research DesignThe research presented in this...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01123/full |
| _version_ | 1828554904719851520 |
|---|---|
| author | Aneta Mela Łukasz A. Poniatowski Łukasz A. Poniatowski Bartłomiej Drop Marzena Furtak-Niczyporuk Janusz Jaroszyński Witold Wrona Anna Staniszewska Jan Dąbrowski Anna Czajka Beata Jagielska Monika Wojciechowska Maciej Niewada |
| author_facet | Aneta Mela Łukasz A. Poniatowski Łukasz A. Poniatowski Bartłomiej Drop Marzena Furtak-Niczyporuk Janusz Jaroszyński Witold Wrona Anna Staniszewska Jan Dąbrowski Anna Czajka Beata Jagielska Monika Wojciechowska Maciej Niewada |
| author_sort | Aneta Mela |
| collection | DOAJ |
| description | BackgroundIn Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients.Research DesignThe research presented in this paper is based on data analysis published by the National Health Fund in Poland. The analysis focused on estimating public payer expenditure on drugs available within drug programmes from 2015 to 2018.ResultsIn subsequent years, reimbursement of drugs used within drug programmes was associated with the National Health Fund budget expenditure of 635 mln USD, 755 mln USD, 854 mln USD, and 921 mln USD, respectively. Reimbursement of oncology drug programmes constituted 48.1%, 42.5%, 47.1%, and 52.4% and were approximately 305, 312, 402, 483 mln USD, whereas values of non-oncology drug programmes were approximately 330, 434, 452, and 438 mln USD which constituted 51.9%, 57.5%, 52.9%, and 47.6% respectively.ConclusionDespite the fact that the expenditure on drug programs in Poland are increasing every year, they undoubtedly improve the patient’s access to the most innovative oncological and nononcological therapies in the Polish healthcare system. |
| first_indexed | 2024-12-12T05:44:05Z |
| format | Article |
| id | doaj.art-b1a81188acd6414f9b509f7bef66c3f6 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-12T05:44:05Z |
| publishDate | 2020-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-b1a81188acd6414f9b509f7bef66c3f62022-12-22T00:35:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-08-011110.3389/fphar.2020.01123549307Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 YearsAneta Mela0Łukasz A. Poniatowski1Łukasz A. Poniatowski2Bartłomiej Drop3Marzena Furtak-Niczyporuk4Janusz Jaroszyński5Witold Wrona6Anna Staniszewska7Jan Dąbrowski8Anna Czajka9Beata Jagielska10Monika Wojciechowska11Maciej Niewada12Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, PolandDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, PolandDepartment of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, PolandDepartment of Information Technology and Medical Statistics, Faculty of Health Sciences, Medical University of Lublin, Lublin, PolandDepartment of Public Health, Faculty of Medicine, Medical University of Lublin, Lublin, PolandChair of Administrative Procedure, Faculty of Law and Administration, Maria Curie-Skłodowska University of Lublin, Lublin, PolandHealthQuest Sp. z o.o., Warsaw, PolandDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, PolandDepartment of Pharmacology, National Medicines Institute, Warsaw, PolandDepartment of Neurology, Czerniakowski Hospital, Warsaw, PolandDepartment of Oncological Diagnostics, Cardiooncology and Palliative Medicine, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland0Department of Pediatric Nephrology, Medical University of Lublin, Lublin, PolandDepartment of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, PolandBackgroundIn Poland drug programmes developed by the Minister of Health and financed by the National Health Fund are special reimbursement frameworks of innovative, expensive, and mostly hospital based medical products used for a small number of patients.Research DesignThe research presented in this paper is based on data analysis published by the National Health Fund in Poland. The analysis focused on estimating public payer expenditure on drugs available within drug programmes from 2015 to 2018.ResultsIn subsequent years, reimbursement of drugs used within drug programmes was associated with the National Health Fund budget expenditure of 635 mln USD, 755 mln USD, 854 mln USD, and 921 mln USD, respectively. Reimbursement of oncology drug programmes constituted 48.1%, 42.5%, 47.1%, and 52.4% and were approximately 305, 312, 402, 483 mln USD, whereas values of non-oncology drug programmes were approximately 330, 434, 452, and 438 mln USD which constituted 51.9%, 57.5%, 52.9%, and 47.6% respectively.ConclusionDespite the fact that the expenditure on drug programs in Poland are increasing every year, they undoubtedly improve the patient’s access to the most innovative oncological and nononcological therapies in the Polish healthcare system.https://www.frontiersin.org/article/10.3389/fphar.2020.01123/fulldrug programmespublic payer expendituresreimbursementcancer drugsdrug therapyhospital medicinal products |
| spellingShingle | Aneta Mela Łukasz A. Poniatowski Łukasz A. Poniatowski Bartłomiej Drop Marzena Furtak-Niczyporuk Janusz Jaroszyński Witold Wrona Anna Staniszewska Jan Dąbrowski Anna Czajka Beata Jagielska Monika Wojciechowska Maciej Niewada Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years Frontiers in Pharmacology drug programmes public payer expenditures reimbursement cancer drugs drug therapy hospital medicinal products |
| title | Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years |
| title_full | Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years |
| title_fullStr | Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years |
| title_full_unstemmed | Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years |
| title_short | Overview and Analysis of the Cost of Drug Programs in Poland: Public Payer Expenditures and Coverage of Cancer and Non-Neoplastic Diseases Related Drug Therapies from 2015–2018 Years |
| title_sort | overview and analysis of the cost of drug programs in poland public payer expenditures and coverage of cancer and non neoplastic diseases related drug therapies from 2015 2018 years |
| topic | drug programmes public payer expenditures reimbursement cancer drugs drug therapy hospital medicinal products |
| url | https://www.frontiersin.org/article/10.3389/fphar.2020.01123/full |
| work_keys_str_mv | AT anetamela overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT łukaszaponiatowski overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT łukaszaponiatowski overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT bartłomiejdrop overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT marzenafurtakniczyporuk overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT januszjaroszynski overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT witoldwrona overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT annastaniszewska overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT jandabrowski overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT annaczajka overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT beatajagielska overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT monikawojciechowska overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years AT maciejniewada overviewandanalysisofthecostofdrugprogramsinpolandpublicpayerexpendituresandcoverageofcancerandnonneoplasticdiseasesrelateddrugtherapiesfrom20152018years |